RT Journal Article
SR Electronic
T1 Randomised Controlled Trial of Intravenous Nafamostat Mesylate in COVID pneumonitis: Phase 1b/2a Experimental Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.06.21264648
DO 10.1101/2021.10.06.21264648
A1 Tom M. Quinn
A1 Erin E. Gaughan
A1 Annya Bruce
A1 Jean Antonelli
A1 Richard O’Connor
A1 Feng Li
A1 Sarah McNamara
A1 Oliver Koch
A1 Claire MacIntosh
A1 David Dockrell
A1 Timothy Walsh
A1 Kevin G. Blyth
A1 Colin Church
A1 Jürgen Schwarze
A1 Cecilia Boz
A1 Asta Valanciute
A1 Matthew Burgess
A1 Philip Emanuel
A1 Bethany Mills
A1 Giulia Rinaldi
A1 Gareth Hardisty
A1 Ross Mills
A1 Emily Findlay
A1 Sunny Jabbal
A1 Andrew Duncan
A1 Sinéad Plant
A1 Adam D. L. Marshall
A1 Irene Young
A1 Kay Russell
A1 Emma Scholefield
A1 Alastair F. Nimmo
A1 Islom B. Nazarov
A1 Grant C. Churchill
A1 James S.O. McCullagh
A1 Kourosh H. Ebrahimi
A1 Colin Ferrett
A1 Kate Templeton
A1 Steve Rannard
A1 Andrew Owen
A1 Anne Moore
A1 Keith Finlayson
A1 Manu Shankar-Hari
A1 John Norrie
A1 Richard A. Parker
A1 Ahsan R. Akram
A1 Daniel C. Anthony
A1 James W. Dear
A1 Nik Hirani
A1 Kevin Dhaliwal
YR 2021
UL http://medrxiv.org/content/early/2021/10/07/2021.10.06.21264648.abstract
AB Despite the success of vaccines and selected repurposed treatments, COVID-19 is likely to remain a global health problem and further chemotherapeutics are required. Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials without characterisation of Pharmacokinetics (PK)/Pharmacodynamics (PD) including safety in COVID-19. One such drug is Nafamostat Mesylate (Nafamostat), a synthetic serine protease inhibitor with anticoagulant and anti-inflammatory properties. Preclinical data has demonstrated that it is has potent antiviral activity against SARS-CoV-2 by directly inhibiting the transmembrane protease serine 2 (TMPRSS2) dependent stage of host cell entry.Methods We present the findings of a phase Ib/II open label, platform randomised controlled trial (RCT), exploring the safety of intravenous Nafamostat in hospitalised patients with confirmed COVID-19 pneumonitis. Patients were assigned randomly to standard of care (SoC), Nafamostat or an alternative therapy. Secondary endpoints included clinical endpoints such as number of oxygen free days and clinical improvement/ deterioration, PK/PD, thromboelastometry, D Dimers, cytokines, immune cell flow cytometry and viral load.Results Data is reported from 42 patients, 21 of which were randomly assigned to receive intravenous Nafamostat. The Nafamostat group developed significantly higher plasma creatinine levels, more adverse events and a lower number of oxygen free days. There were no other statistically significant differences in the primary or secondary endpoints between Nafamostat and SoC. PK data demonstrated that intravenous Nafamostat was rapidly broken down to inactive metabolites. We observed an antifibrinolytic profile, and no significant anticoagulant effects in thromboelastometry. Participants in the Nafamostat group had higher D Dimers compared to SoC. There were no differences in cytokine profile and immune cell phenotype and viral loads between the groups.Conclusion In hospitalised patients with COVID-19, we did not observe evidence of anti-inflammatory, anticoagulant or antiviral activity with intravenous Nafamostat. Given the number of negative trials with repurposed drugs, our experimental medicine trial highlights the value of PK/PD studies prior to selecting drugs for efficacy trials. Given the mechanism of action, further evaluation of Nafamostat delivered via a different route may be warranted. This trial demonstrates the importance of experimental trials in new disease entities such as COVID-19 prior to selecting drugs for larger trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04473053Clinical Protocols https://www.medrxiv.org/content/10.1101/2021.05.20.21257513v1 Funding StatementThis work was supported by LifeArc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The DEFINE trial has received full ethical approval from Scotland A REC (20/SS/0066), the MHRA (EudraCT 2020-002230-32) and NHS Lothian.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOwnership of the data arising from this study resides with the study team. Scientific publications and the sharing of clinical data generated as part of this trial is crucial to better understanding COVID-19 and developing new treatments. As such, the results will be submitted for publication in a peer-reviewed journal. Data will be shared with larger clinical trial networks, including RECOVERY.